Shots:AstraZeneca has reported P-III (NATRON) trial data assessing Fasenra (30mg, SC, Q4W) vs PBO, both in addition to background HES therapy in 133 HES pts for 24wks.Trial met its 1EP of delayed time to first HES worsening or flare & reduced the risk of HES worsening/flare by 65%Trial met all 2EPs, showing…
